FRANKLIN LAKES, NJ, Sept. 21, 2021 / PRNewswire / – BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world’s leading medical technology companies, today announced it has been selected by the state from Washington as read, rapid antigen test option for COVID-19 testing and screening at K-12 schools across the state.

The BD Veritor ™ Plus System is a portable, quick and easy-to-use point-of-care antigen test that detects SARS-CoV-2 – the novel coronavirus that causes COVID-19 – and delivers results in just 15 minutes with a Clear and easy to read “positive” or “negative” reading on its digital display. The digital display eliminates human subjectivity from manually read tests. Schools in Washington State can use the BD Veritor ™ Plus system for free through a partnership with the Washington Department of Health and the Health Commons Project’s “Learn to Return” school assessment program.

Schools that choose to use the BD Veritor ™ Plus system also have a full service option where Premier Medical Group (PMG), a third-party testing company, schedules and runs the school’s testing program so that teachers and administrators can focus on teaching, not testing. In this option, PMG will prepare a turnkey solution that includes the test protocol, administration of tests to students and completion of all required results reports to individuals and schools, as well as health officials. local, state and federal. This will be the only rapid test option (same day results) with staff support for schools in Washington.

“With these testing services, schools can benefit from BD’s diagnostic testing technologies as well as the ease of implementation and execution of a well-known testing service provider who has experience in implementing on-site testing programs in over 500 schools nationwide, ”said Dr. Scott Miscovich. , President and CEO, PMG. “Knowing test results in 15 minutes is essential in school environments in order to stay open and help contain the spread of COVID-19. Students can be quarantined immediately if they are positive, instead of waiting 24 to 48 hours or more for a required or recommended to ensure the safety of participants and reduce the risk of major outbreaks within a team that can lead to games or canceled seasons. “

The rapid antigen test with the BD Veritor ™ Plus System meets the needs of Washington schools that implement symptomatic testing, screening programs and / or after-school testing only. Washington school officials interested in using the BD Veritor ™ Plus System should contact

About the BD Veritor ™ Plus System This product has not been authorized or approved by the FDA; but has been cleared by the FDA under an EUA for use by authorized laboratories; This product has only been authorized for the detection of SARS-CoV-2 proteins, not for other viruses or pathogens; and, This product is only authorized for the duration of the declaration that there are circumstances justifying the authorization of the emergency use of in vitro diagnostics for the detection and / or diagnosis of COVID-19 under Federal Food, Drug and Cosmetic Act, Section 564 (b) (1), 21 USC § 360bbb-3 (b) (1), unless the statement is terminated or the authorization is earlier revoked . Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 USC §263a, which meet the requirements for performing moderate, high, or waived complexity tests. This test is licensed for point-of-care (POC) use, that is, in patient care facilities operating under a CLIA certificate of exemption, certificate of compliance, or certificate of accreditation. For more information, please see

About BD BD is one of the world’s largest medical technology companies, advancing the healthcare world by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the front lines of healthcare by developing innovative technologies, services and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 70,000 employees have the passion and commitment to help improve the safety and efficiency of the process of providing care for clinicians, enable laboratory scientists to accurately detect disease and advance patient care. capacities of researchers to develop the next generation of diagnostics and therapies. BD has a presence in virtually every country and partners with organizations around the world to solve some of the world’s toughest health problems. By working closely with its customers, BD can help improve results, reduce costs, increase efficiency, improve safety and expand access to healthcare. For more information on BD, please visit or connect with us on LinkedIn at and Twitter @BDandCo.

View original content to download multimedia:

SOURCE BD (Becton, Dickinson and company)

Recent stories you might have missed

Copyright © 2021 PR Newswire Association LLC. All rights reserved.

Source link

Recommended Posts